This preprint reports analysis of residues from 3,168 used syringes collected by harm reduction organizations in Jefferson County, Kentucky, between January and December 2025. The objective was to characterize prevalent adulterants and polysubstance combinations circulating in the local unregulated drug supply and to identify research priorities that could inform clinical, preclinical, and translational work.
The authors emphasize that harm reduction syringe exchange programs offer a practical sampling frame for rapid, population-relevant chemical surveillance of injected substances.
Used syringes (N = 3,168) were obtained from several harm reduction organizations. Residues were analyzed using gas chromatography–mass spectrometry (GC-MS) to identify compounds present. Compounds were classified into categories including recreational drugs, adulterants (for example, diphenhydramine), and byproducts/precursors of synthesis (for example, 4-ANPP). Byproducts and synthetic precursors were excluded from the primary prevalence analyses reported.
Ethical approvals and participant protections were declared by the authors; funding sources included the National Institute on Drug Abuse and other translational science institutions. The manuscript is a preprint and has not undergone peer review.
Of the 3,168 syringes analyzed, 2,522 (79.61%) tested positive for one or more compounds after exclusion of byproducts/precursors. The prevalence data form the basis for characterizing both single-substance detection and combinations of substances in residues.
Among syringes with positive findings, the top recreational substances identified were methamphetamine (meth) (n = 1,387; 54.99%), fentanyl (n = 1,220; 48.37%), and heroin (n = 653; 25.89%). These counts reflect presence in syringe residues rather than measures of dose or purity.
The detection of both stimulants (meth) and potent synthetic opioids (fentanyl) indicates substantial opioid-stimulant polysubstance circulation in this sample.
Adulterants were frequently present alongside recreational drugs in syringe residues. The most common adulterants reported were diphenhydramine (DPH) (n = 1,021; 40.48% of positives), dimethyl sulfone (n = 749; 29.69%), and lidocaine (n = 736; 29.18%).
The presence of these agents—antihistamines, a sulfone, and a local anesthetic—highlights the complex composition of street drug preparations and potential contributions to clinical effects or toxicity when co‑ingested or co‑injected with opioids and stimulants.
The study enumerated common binary and tertiary combinations involving at least one recreational drug. The most frequent pairs were:
The most frequent three-substance combinations included:
These findings demonstrate repeated co-occurrence of fentanyl with both other opioids (heroin) and stimulants (meth), often with common adulterants such as diphenhydramine and lidocaine.
The authors interpret these residue patterns as evidence of evolving multiple-opioid and opioid-stimulant polysubstance use in the region sampled. They propose that such chemical surveillance can rapidly inform several research priorities:
The authors suggest that data from syringe residue analysis can accelerate the development of novel therapeutics and targeted interventions by aligning laboratory models and clinical research with real-world drug composition patterns.
This report is a preprint and has not been peer reviewed; the authors explicitly note that findings should not be used to guide clinical practice without further validation. The source reports that byproducts and precursors were excluded from the primary prevalence analysis; other methodological details beyond what is summarized here (for example, limits of detection, quantitative measures, or participant-level demographic linkage) were not specified in the abstracted source text.
Competing interests were declared as none. The study received funding from the National Institute on Drug Abuse and related translational science programs as reported in the source.
Overall, the syringe residue analysis identified high prevalence of fentanyl, methamphetamine, and common adulterants such as diphenhydramine, and documented frequent co-occurrence of these substances in pairs and trios, supporting the need to incorporate polysubstance and adulterant exposures into ongoing clinical and laboratory research agendas.